The PIM1 Kinase Is a Critical Component of a Survival Pathway Activated by Docetaxel and Promotes Survival of Docetaxel-treated Prostate Cancer Cells
Open Access
- 1 July 2008
- journal article
- Published by Elsevier BV
- Vol. 283 (30), 20635-20644
- https://doi.org/10.1074/jbc.m709479200
Abstract
No abstract availableThis publication has 82 references indexed in Scilit:
- The Role of Oxidative Stress in Hormesis Induced by Sodium Arsenite in Human Embryo Lung Fibroblast (HELF) Cellular Proliferation ModelJournal of Toxicology and Environmental Health, Part A, 2007
- Apoptotic Cell Death Induced by Low-Dose Radiation in Male Germ Cells: Hormesis and AdaptationCritical Reviews in Toxicology, 2007
- Docetaxel induces apoptosis in hormone refractory prostate carcinomas during multiple treatment cyclesBritish Journal of Cancer, 2006
- Chemotherapy-induced epidermal growth factor receptor activation determines response to combined gefitinib/chemotherapy treatment in non–small cell lung cancer cellsMolecular Cancer Therapeutics, 2006
- Novel role of Stat1 in the development of docetaxel resistance in prostate tumor cellsOncogene, 2006
- Clinical Pharmacokinetics of DocetaxelClinical Pharmacokinetics, 2006
- Down-Regulation of Signal Transducer and Activator of Transcription 3 Expression Using Vector-Based Small Interfering RNAs Suppresses Growth of Human Prostate Tumor In vivoClinical Cancer Research, 2005
- Pim‐1 kinase promotes inactivation of the pro‐apoptotic Bad protein by phosphorylating it on the Ser112 gatekeeper siteFEBS Letters, 2004
- Delineation of prognostic biomarkers in prostate cancerNature, 2001
- Paclitaxel Induces Prolonged Activation of the Ras/MEK/ERK Pathway Independently of Activating the Programmed Cell Death MachineryPublished by Elsevier BV ,2001